Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial

MLA

Karl Heinz Weiss, et al. “Efficacy and Safety of ALXN1840 versus Standard of Care in Wilson Disease: Primary Results from an Ongoing Phase 3, Randomized, Controlled, Rater-Blinded Trial.” Journal of Hepatology, vol. 77, July 2022, p. S1. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7d64f3b540bd404b6f45782583ac5d3b&authtype=sso&custid=ns315887.

APA

Karl Heinz Weiss, Michael Schilsky, Anna Czlonkowska, Fred Askari, Aftab Ala, Peter Ferenci, Peter Ott, Dzhamal Abdurakhmanov, Ferenc Szalay, Piotr Socha, Norikazu Shimizu, Jeff Bronstein, Danny Bega, Sihoun Hahn, Eugene Swenson, Yi Chen, & Aurelia Poujois. (2022). Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. Journal of Hepatology, 77, S1.

Chicago

Karl Heinz Weiss, Michael Schilsky, Anna Czlonkowska, Fred Askari, Aftab Ala, Peter Ferenci, Peter Ott, et al. 2022. “Efficacy and Safety of ALXN1840 versus Standard of Care in Wilson Disease: Primary Results from an Ongoing Phase 3, Randomized, Controlled, Rater-Blinded Trial.” Journal of Hepatology 77 (July): S1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7d64f3b540bd404b6f45782583ac5d3b&authtype=sso&custid=ns315887.